{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-038079","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.067484+00:00","generated_at":"2026-05-16T12:55:32.231879+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors","bullets":["WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.","Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.","Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.","Compassionate use in 3 additional children with high-grade glioma also evaluated.","Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-038079","json":"https://secwatch.observer/filing/0001437749-25-038079.json","markdown":"https://secwatch.observer/filing/0001437749-25-038079.md","text":"https://secwatch.observer/filing/0001437749-25-038079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/0001437749-25-038079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/mbrx20251216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:55:32.231879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}